50% of patients treated with Kanuma experience reduced liver fibrosis: 3 study insights

New Haven, Conn.-based Alexion Pharmaceuticals has released data from studies related to the Phase 3 ARISE trial of Kanuma. Kanuma, or sebelipase alfa, is a drug treatment for lysosomal acid lipase deficiency.

Here's what you need to know:

1. Two-thirds of patients treated with Kanuma for 52 weeks experienced reduced liver fibrosis.

2. Half of patients treated with Kanuma for 52 weeks experienced at least a two-stage reduction in liver fibrosis.

3. Kanuma-treated patients also experienced improvements in alanine aminotransferase, LDL cholesterol and liver fat content.

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy.
 

Articles We Think You'll Like